Keapstone Therapeutics Limited secures further £1 million investment from
Parkinson’s UK
Keapstone Therapeutics Limited, a single-asset virtual biotech with an innovative disease-modifying therapeutic approach to motor neuron...
Novel gene transcription modulators programme on track
Parkinson’s UK is pleased to announce the release of the next tranche of funding to continue our collaboration with Selcia (part of...
Positive progress towards a new treatment for dyskinesia
Parkinson’s UK is pleased to announce the release of the next tranche of funding to US company Neurolixis to continue final pre-clinical...
Keapstone Therapeutics website launched
We're pleased to announce that Keapstone Therapeutics, a spin-out company formed as part of the Parkinson's Virtual Biotech, now has it's...
Business Development Consultant:
invitation for applications
KEAPSTONE THERAPEUTICS was created in February 2017 as a single-asset virtual biotech company, spun out of University of Sheffield with seed
Parkinson’s UK, Selcia, and Cresset collaborate to discover new drug candidates for Parkinson’s
A new collaboration in the efforts to find a new drug candidate to combat Parkinson’s has been announced in the UK today. The...